Stockscreener 앱 받기
33.23
10.77%
3.23
전일 마감가:
$30.00
열려 있는:
$28.9906
하루 거래량:
8,851
Relative Volume:
0.22
시가총액:
$33.80M
수익:
순이익/손실:
주가수익비율:
-
EPS:
-
순현금흐름:
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$25.13
$33.71
52주 변동 폭
$25.13
$33.71
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Company Profile
Compare IRLA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRLA
IRulya Therapeutics Inc. Common Stock
|
33.23 | 33.80M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-09 | 개시 | Raymond James | Outperform |
| 2026-09-24 | 개시 | Rodman & Renshaw | Buy |
| 2026-09-22 | 업그레이드 | Citizens | Mkt Perform → Mkt Outperform |
| 2026-08-20 | 개시 | Craig Hallum | Buy |
| 2026-07-29 | 개시 | Oppenheimer | Outperform |
| 2026-06-24 | 개시 | Leerink Partners | Outperform |
| 2026-06-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-01-30 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-03-24 | 개시 | Oppenheimer | Outperform |
모두보기
IRulya Therapeutics Inc. Common Stock 주식(IRLA)의 최신 뉴스
Quince Therapeutics relaunched as IRulya: Raymond James targeted QNCX stock at USD 72 - ad-hoc-news.de
IRulya Therapeutics Inc. (IRLA) Company Information - Simply Wall Street
IRulya Therapeutics (Nasdaq:IRLA)Stock Analysis - Simply Wall Street
Diluted net income available to common stockholders of IRulya Therapeutics Inc. – NASDAQ:IRLA - TradingView
Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger - Fierce Pharma
Quince Therapeutics rebrands as IRulya, names new CEO - Investing.com
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease - GlobeNewswire
A $116 million cash balance on June 30, 2026, is expected to fund IRulya's operations through 2028. - Stock Titan
IRulya Therapeutics Inc. Common Stock (IRLA) 재무 분석
IRulya Therapeutics Inc. Common Stock (IRLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.35%
자본화:
|
볼륨(24시간):